Get the Stockscreener App
2.965
4.04%
0.115
Genelux Corp stock is traded at $2.965, with a volume of 98,783.
It is up +4.04% in the last 24 hours and up +4.04% over the past month.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
See More
Previous Close:
$2.85
Open:
$2.88
24h Volume:
98,783
Relative Volume:
0.52
Market Cap:
$132.95M
Revenue:
$8,000
Net Income/Loss:
$-33.58M
P/E Ratio:
-3.4731
EPS:
-0.8537
Net Cash Flow:
$-27.88M
1W Performance:
+2.95%
1M Performance:
+4.04%
6M Performance:
-29.24%
1Y Performance:
+1.54%
1-Day Range:
$2.83
$2.98
1-Week Range:
$2.67
$3.11
52-Week Range:
$2.29
$8.535
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.965 | 132.95M | 8,000 | -33.58M | -27.88M | -0.8537 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Lake Street | Buy |
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
View All
Genelux Corp Stock (GNLX) Latest News
GENELUX (GNLX) CFO receives 278,906 restricted stock units as equity grant - Stock Titan
Genelux (NASDAQ: GNLX) grants 233,957 RSUs to General Counsel Eric Groen - Stock Titan
GENELUX (GNLX) CTO granted 174,841 RSUs under 2022 equity plan - Stock Titan
GENELUX (NASDAQ: GNLX) director James L. Tyree receives RSU and option grants - Stock Titan
Genelux (NASDAQ: GNLX) grants CEO 730,601 RSUs under 2022 plan - Stock Titan
Genelux (GNLX) director receives RSU and stock option grants - Stock Titan
Genelux (GNLX) director receives RSUs and stock options in new grant - Stock Titan
GENELUX (GNLX) Chief Scientific Officer awarded 119,318 RSUs in equity grant - Stock Titan
GENELUX (NASDAQ: GNLX) director granted RSUs and options in new equity awards - Stock Titan
Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Genelux Corp (GNLX) Institutional Confidence - TradingKey
Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Genelux Corp (GNLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genelux Corp (GNLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Genelux Corp (GNLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Genelux Corp (GNLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genelux head of regulatory Ralph Smalling sells $562 in stock By Investing.com - Investing.com India
Tax-related share sale by Genelux (GNLX) Head of Regulatory - Stock Titan
Genelux head of regulatory Ralph Smalling sells $562 in stock - Investing.com
Genelux director Thomas John sold $29,801 in company stock By Investing.com - Investing.com India
Insider Sell: John Thomas Sells 10,000 Shares of Genelux Corp (G - GuruFocus
Genelux director Thomas John sold $29,801 in company stock - Investing.com
GENELUX (NASDAQ: GNLX) director sells 10,000 shares in Rule 10b5-1 trade - Stock Titan
Genelux Corp. Financial Disclosures & SEC Filings - TradingView
GNLX (NASDAQ) director sells 10,000 shares via 10b5-1, $28,957 proceeds - Stock Titan
GNLX Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Development Stage; Stock Edges HigherAnnual Earnings Summary - newsline.com
GNLX Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEarnings Surprise Stocks - newsline.com
GNLX SEC FilingsGenelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan
GNLX Technical Analysis | Trend, Signals & Chart Patterns | GENELUX CORP (NASDAQ:GNLX) - ChartMill
Genelux president and CEO Zindrick Thomas sells $8,225 in stock By Investing.com - Investing.com Nigeria
Genelux CSO Yu Yong sells $1,798 of common stock - Investing.com UK
Genelux CSO Yu Yong sells $1,798 of common stock By Investing.com - Investing.com Nigeria
Genelux CTO Joseph Cappello sells $1,799 in company stock By Investing.com - Investing.com South Africa
Genelux head of regulatory sells $804 in stock By Investing.com - Investing.com Nigeria
Genelux president and CEO Zindrick Thomas sells $8,225 in stock - Investing.com
Genelux CTO Joseph Cappello sells $1,799 in company stock - Investing.com
Genelux head of regulatory sells $804 in stock - Investing.com
Genelux (GNLX) CSO Yu Yong sells 605 shares to cover RSU tax bill - Stock Titan
Research Analysts Offer Predictions for Genelux Q2 Earnings - MarketBeat
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):